Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Definitions

• This invention relates to hormone replacement therapy tor menopausal or castrate women.
• this invention relates to a form of a preparation and method which involves transdermal delivery.
• Estrogen replacement therapy is warranted in menopausal women for several reasons. Estrogen replacement is known to relieve hot flushes and this relief of flushes and night sweats improves sleep patterns and contributes to the patient's general feeling of well-being. Estrogen replacement protects against postmenopausal loss of calcium from the skeleton, especially from vertebral bodies, preventing crush fractures and loss of body height.
• Estrogen replacement protects against postmenopausal loss of calcium from the skeleton, especially from vertebral bodies, preventing crush fractures and loss of body height.
• long-term estrogen therapy is also associated with a reduction in the incidence of classical osteoporotic fractures of the forearm and hip. Another beneficial effect of long-term estrogen use is the reduction of the risk of death from ischemic heart disease probably mediated by changes in blood lipoprotein concentrations.
• Estrogen replacement has also been shown to improve the vascuiarity and health of the vaginal mucosa and urinary tract.
• the addition of a progestin for 13 days each month has been demonstrated to protect the endometrium from these stimulatory effects of estrogen.
• Progestin protects the endometrium by reducing nuclear estradiol receptor concentration and thereby decreasing nuclear estrogen bioavailability resulting in an antimitotic effect and lowering DNA synthesis.
• Progestins also increase the activity of endometrial estradiol- 17(->-dehydrogenase, an enzyme which metabolizes estradiol to estrone, a less potent estrogen.
• concerns have been expressed about the potential adverse effects of progestin in suppressing high density lipoprotein cholesterol concentrations. This cholesterol fraction appears to have a protective effect against ischemic heart disease and atherosclerosis. The lowering of HDL cholesterol by progestin could negate the long-term beneficial effects of estrogen in reducing the incidence of myocardial infraction.
• progestins include acne, breast tenderness, depression and irritability. Since the side effects of progestins appear to be dose dependent, the dose of progestin used with postmenopausal estrogen replacement should be the minimum necessary to achieve endometrial protection.
• progestin administration is preceded by up to 13-16 days of unopposed estrogen therapy with endometrial proliferation and estrogen and progestin receptor induction, it is possible that a high dose of progestin is required to antagonize these effects resulting in a greater chance of side effects and adverse metabolic effects.
• newer continuous low dose estrogen and progestin regimens for hormonal replacement may avoid the problem of withdrawal bleeding, daily administration of a progestin in these regimens induces depletion of both estrogen and progestin receptors resulting in endometrial atrophy which may be associated with breakthrough bleeding.
• endometrium is more sensitive to subsequent progestin activity which limits growth by decreasing estrogen receptors and increasing 17 ⁇ -hydroxystero ⁇ d dehydrogenase.
• Interaction ot progestin with progestin receptors induces secretory changes in the endometrium which results in a denser stroma and endometrial stability.
• a return to relatively dominant estrogenic activity then again stimulates estrogen and progestin receptors and renews endometrial sensitivity to progestin.
• This push/pull activity keeps endometrial activity within a low range depending on the number ot days ot estrogenic and progestagenic activity and maintains a stable endometrium resulting in the substantial absence ot breakthrough or withdrawal bleeding.
• This formulation allows better progestational effects with less progestin.
• the dose ot progestin is significantly decreased compared with a preparation containing a constant daily dosage ot a progestin.
• a total steroid dosage can be achieved which is similar to or even lower than that of the present cyclic method ot administering estrogen and progestin tor hormonal replacement therapy of ovarian failure.
• a reduction in progestin dosage results in less negative impact on HDL cholesterol levels.
• Transdermal drug delivery systems are known in the art. Some patents in this area are concerned with the transdermal delivery of hormone formulations for various purposes. Examples of such patents are as follows: U.S. Patent No. 4.816,258 issued March 28, 1989 to Nedberge et al discloses a drug formulation of ethinyl estradiol and levo-norgestrel for transdermal administration which comprises a matrix containing the steroids and a skin permeation enhancing amount of glycerol mono-oleate. U.S. Patent No. 5, 122,382 issued June 16, 1992 to Gail et al discloses a composition for transdermal administration comprising an estrogen and ST-1435. The formulation delivers certain quantities per day of the steroids and includes a skin permeation enhancer.
• transdermal delivery systems are perceived to exist primarily in the ability to bypass the liver on the "first pass" of the hormones through the body, by not delivering them orally.
• Gastrointestinal absorption requires transit through the liver, and metabolism of the drug occurs there, before the first complete circulatory loop, takes the drug to the target organs (i.e. , uterus, heart, bones, central nervous system, etc. ).
• the advantage of avoiding the liver is that lower amounts of the drug can be given to a patient in order to achieve the same degree of efficacy in target tissues, thereby diminishing the untoward metabolic effects (e.g. , changes in coagulation factors, glucose metabolism, iipids, etc.) that would be encountered via the oral route. (See Transdermal Hormone Replacement, M.I. Whitehead and L.
• a continuous transdermal delivery system generally provides more constant steady-state plasma levels of hormones, devoid of peaks and valleys, than does a once daily oral administration.
• the "first pass” phenomenon could also be argued to underlie the perceived disadvantage of the transdermal delivery route.
• This perceived disadvantage is that estrogens actually induce some favourable changes in the lipoprotein profile (stimulating increases in HDL cholesterol, for example) and these effects are likely the result of induction of liver enzymes. Diminishing hepatic exposure to the drug could be predicted to diminish the beneficial effects of these drugs.
• the factors in favour of transdermal include a patient who is very sensitive to pharmacological agents in general, a noncompliant or forgetful patient who may have difficulty with daily dosing regimens, gastrointestinal disturbances from oral estrogen therapy and a lack of response to the oral route.
• the selection of the oral form might be preferable in the case where a patient is perceived to have a high risk for cardiovascular disease, hyperlipidemia, a tendency to dermal sensitivity and dermatologic disorders.
• transdermal delivery system for the regimen of U.S. Patent No. 5, 108,995 would enhance the benefits of the basic regimen on its own because of the perceived advantages of the transdermal route.
• transdermal delivery system works best with a particular selection of hormones which are most suitable for this delivery route.
• the invention provides a method of treating a female in need of hormone replacement therapy comprising transdermally administering to said female, a pharmaceutical patch regimen series arranged in alternating phases of dominant hormone activity of from about one day to about four days, said phases being selected from estrogen dominant activity phases and progestin dominant activity phases, each of said phases comprising at least one patch which is applied and removed in accordance with the particular dominant phase activity, wherein the estrogen dominant activity phase contains an amount of a substance exhibiting estrogen activity sufficient to promote the development of progestin receptors in the endometrium of said female, or an amount of a substance exhibiting estrogen activity sufficient to promote the development of progestin receptors in the endometrium of said female and an amount of a substance exhibiting progestin activity; and wherein the progestin dominant activity phases contain an amount of a substance exhibiting estrogen activity and an amount of a substance exhibiting progestin activity sufficient to antagonize the effect of estrogen on the endometrium of said female, and the estrogen and progestin are selected from
• the present invention provides a method ot treating a temale in need ot hormone replacement therapy comprising transdermally administering, to said temale a pharmaceutical patch regimen series arranged in alternating phases ot dominant hormone activity ot from about one dav to about tour days, said phases being selected from estrogen dominant activity phases and progestin dominant activity phases, each ot said phases comprising at least one patch which is applied and removed in accordance with the particular dominant phase activity, said estrogen dominant activity phase consisting ot administering a transdermal estrogen substance alone or administering a transdermal estrogen substance and a transdermal progestin substance, and said progestin dominant activity phase consisting ot administering a transdermal progestin substance and a transdermal estrogen substance, the amount ot progestin substance being alternately increased in the progestin dominant activity phase and decreased in the estrogen dominant activity phase to provide the required dominant activity.
• the invention provides a pharmaceutical preparation tor administration to a temale in need ot hormone replacement therapy comprising a patch regimen series arranged in alternating phases ot dominant hormone activity ot from about one day to about tour days, each ot said phases being selected from estrogen dominant activity phases and progestin dominant activity phases, each ot said phases comprising at least one patch which is applied and removed in accordance with the particular dominant phase activity, said estrogen dominant activity phase consisting ot a transdermal estrogen substance alone or a transdermal estrogen substance and a transdermal progestin substance, and said progestin dominant activity phase consisting ot a transdermal progestin substance and a transdermal estrogen substance, the amount ot progestin substance being alternately increased in the progestin dominant activity phase and decreased in the estrogen dominant activity phase to provide the required dominant activity.
• the invention provides a package comprising a pharmaceutical transdermal patch regimen for administration, to a female in need of hormone replacement therapy wherein the package consists of a pharmaceutical patch regimen series arranged in alternating phases of dominant hormone activity of from about one day to about four days, each of said phases being selected from estrogen dominant activity phases and progestin dominant activity phases, each of said phases comprising at least one patch which is applied and removed in accordance with the particular dominant phase activity, said estrogen dominant activity phase consisting of a transdermal estrogen substance alone or a transdermal estrogen substance and a transdermal progestin substance, and said progestin dominant activity phase consisting of a transdermal progestin substance and a transdermal estrogen substance, the amount of progestin substance being alternately increased in the progestin dominant activity phase and decreased in the estrogen dominant activity phase to provide the required dominant activity.
• the estrogen and progestin are selected from transdermal estrogens and progestins which provide levels of activity, equivalent to a transdermal delivery rate of from about 25 ⁇ g/day to about 150 ⁇ g/day, more preferably about 100 ⁇ g/day of 17- ⁇ estradiol and from about 250 ⁇ g/day to about 500 ⁇ g/day of piperazine estrone sulphate and from about 15 ⁇ g/day, more preferably about 25 ⁇ g/day to about 1000 ⁇ g/day of norethindrone acetate or from about 5 ⁇ g/day to about 150 ⁇ g/day of 3-keto-desogestrel. with the proviso that the progestin is increased in the progestin dominant phase relative to the estrogen dominant phase to produce the required dominance.
• a first patch for example either an adhesive matrix type or a drug reservoir type (ethanolic gel) is prepared containing sufficient 17- ⁇ estradiol to provide a transdermal delivery rate of from about 25 ⁇ g/day to about 100 ⁇ g/day.
• a second patch is prepared, either adhesive matrix or drug reservoir (ethanolic gel) type containing sufficient 17- ⁇ estradiol to give the above release rate and sufficient norethindrone acetate (NETA) to provide a transdermal delivery rate of from about 25 ⁇ g/day to about 1000 ⁇ g/day of NETA, more preferably from about 75 ⁇ g/day to about 500 ⁇ g/day, most preferably 75 ⁇ g/day to about 300 ⁇ g/day.
• NETA norethindrone acetate
• the amount of 17- ⁇ estradiol remains the same as set out above, while the amount of 3-keto-desogestrel is sufficient to provide a transdermal delivery rate of from about 5 ⁇ g/day to about 150 ⁇ g/day. more preferably 25 ⁇ g/day to about 150 ⁇ g/day. It is the application of these patches in the required sequence which provides the advantage of the present invention.
• the estrogens which may be employed as a component in the regimens of this invention may be any of those conventionally available which can be absorbed through the skin. Typically, the estrogen may be selected from the group comprising synthetic and natural estrogens.
• the synthetic estrogens may be selected from, for example, ethinyl estradiol, micronized estradiol, 17- ⁇ estradiol, mestranol. estradiol valerate, 1 1-nitrato estradiol,
• the progestin component may be any progestationally active compound.
• the progestin may be selected from progesterone,
• norgestrel levo-norgestrel, gestodene, delta- 15-levonorgestrel, norgestimate. 17-deacetyl norgestimate, nomegesterol, nesterone.
• desogestrel and 3-keto-desogestrel Preferred progestins are norethindrone acetate and 3-keto-desogestrel.
• the selection of hormones most suited for transdermal delivery may be determined by conventional tests used in the art to determine skin permeability. The most common is the In Vitro Skin Permeation Chamber using hairless mouse skin or human cadaver skin. The literature contains much information on these tests and the following references are typical: a) Kao J, Hall J. Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: In Vitro Studies with Mouse Skin in Organ
• Suitable hormones skin permeation and hence transdermal delivery rates are important, but also, the stability of the hormones in the formulation can be a factor. Stability can be assessed or measured in two basic ways: visual inspection and in vitro dissolution. Visual inspection is generally conducted on both a macroscopic and a microscopic level for crystal formation. As for in vitro dissolution, there are tests for in vitro release rates which are standard in the art. Generally when these criteria are met, the transdermal delivery rates required are readily achieved.
• the phases may comprise from one to four days, but these days need not be exactly twenty-four hour days. Obviously there are limits as to the flexibility available given that absence of hormone for too long would likely result in withdrawal bleeding, but for example, for a three day phase, the total number of hours might be 66 or 78. as opposed to 72.
• a preferred regimen uses phases comprising about three and about four days. Other combinations such as two and three or one and three, or three and three, or two and four, or one and four may be used. Generally hormone replacement therapy is delivered without interruption.
• estradiol containing placebo or any other hormone-free agent may be included in a package.
• suitable alternative hormone-free agents include vitamins, such as iron supplements.
• the quantities of estrogen and progestin incorporated in the formulation of the invention are dependent on the activity of the estrogen or progestin selected.
• estrogen is administered continuously, in other words, it is always present in the formulation, while the progestin level is adjusted up or down to produce the required estrogen or progestin dominance. The selection of quantities is dependent on the type of estrogen or progestin since each hormone has its own specific activity.
• the amount of estrogen activity per unit dose may be equivalent in estrogenic activity to a range of from a minimum of about 0.3 mg of piperazine estrone sulphate to a maximum of about 2.5 mg of piperazine estrone sulphate.
• the amount of progestin activity per unit dose may be equivalent in progestagenic activity to a range of from a minimum of 0 mg to a maximum of about 5 mg of norethindrone.
• Equivalent dosages tor transdermal can be determined from hormone blood level measurements.
• the amounts ot hormones may be characterized as follows. Firstly, each phase would generally constitute a single patch, though a series ot patches could be used to make up a phase. Patch size is dependent on, among other parameters, the length of the phase, and the potency of the hormone. For example, patches of 17- ⁇ estradiol are currently available which provide transdermal delivery rates of about 50 ⁇ g/day. In such instance, the amount of 17- ⁇ estradiol is 4 mg and the size of the patch is about 18 cm" with the actual reservoir being about 10 c ⁇ r.
• the amounts of same would be 10 mg and 30 mg, respectively and the patch surface area would be 26 cnr to provide transdermal delivery rates of about 50 ⁇ g/day for 17- ⁇ estradiol and about 250 ⁇ g/day tor norethindrone acetate.
• 3-Keto-desogestrel is a more potent progestin and the amount incorporated in a patch might range from about 4 mg to about 30 mg to provide the required daily transdermal delivery rates.
• the range for 17- ⁇ estradiol may be from about I mg to about 10 mg (in adhesive matrix reservoir, this could change in another type ot patch), and for norethindrone acetate, the range may be from about 10 mg to about 100 mg.
• the above combinations may also be grouped into three's and four's. starting with either three or four day groups and ending with the other.
• transdermal patches there are a number of transdermal patches available commercially which may be used in the present method. Most important to remember is that the sequence of administration is critical to the present invention and the arrangement of the patches or their application in the predetermined order must be effected for the benefits of the invention to be obtained. Two such patches are described here for purposes of exemplification only, but others may be employed.
• a matrix of a solid adhesive of acrylic copolymer base containing hormones in dissolved form is employed.
• the system involves the use of a flexible backing foil which may comprise for example polyethylene terephthalate.
• a release liner forms another layer (in contact with the adhesive).
• a swellable polysaccharide, galactomannan is added to the adhesive matrix to improve the adhesion between the surface of the patch and hydrated skin, over the whole application, and to reduce irritation phenomena caused by occlusion effects.
• a three layer laminate is produced of the backing foil, drug matrix and release liner.
• SYSTEN TTS a commercial product of this nature is sold under the trade mark SYSTEN TTS.
• ESTRADERMTM is an estradiol transdermal system designed to release estradiol through a rate-limiting membrane continuously upon application to intact skin.
• the ESTRADERMTM system comprises five layers: a backing layer, a drug reservoir, a control membrane, an adhesive layer and a protective layer in that order from outside to inside.
• the qualitative composition of the ESTRADERM drug reservoir is estradiol, alcohol and hydroxy propylcellulose.
• any suitable form of patch may be selected. Another which is known to be useful in the administration of hormone formulations is described in detail in U.S. Patent No. 4.668,232 issued May 26.
• the system described is a four layer system comprising an impermeable backing or covering layer: a reservoir layer adjacent to the backing or covering layer; an adhesive layer permeable to the hormones and a protective layer which is removed before application of the patch.
• a three layer system may be used which comprises a backing layer, a drug matrix adhesive layer and a release liner.
• An estrogen patch for the present invention may be prepared using an ethanolic gel type of drug reservoir.
• the weight of hormone, preferably 17- ⁇ estradiol may comprise 4 mg.
• the patch may have a surface area of about 18 c ⁇ r. In appearance it may be round with the reservoir comprising about 10 cnr of the patch. This generally provides a transdermal delivery rate of about 10 ⁇ g/day for 17- ⁇ estradiol.
• An estrogen/progestin patch may be prepared using an ethanolic gel type of drug reservoir with the amounts of hormones comprising 10 mg of 17- ⁇ estradiol and 30 mg of norethindrone acetate, for example.
• the total contact area of such a patch would be about 20 c ⁇ r and have the appearance of eyeglasses with two joined reservoirs with each reservoir containing both drugs. This generally provides a transdermal delivery rate of about 50 ⁇ g/day of 17- ⁇ estradiol and about 250 ⁇ g/day of norethindrone acetate.
• this preparation is for administration to post menopausal patients and/or those who are actively symptomatic.
• the patches may be packaged, for example, in cartons containing a number of transdermal 17- ⁇ estradiol patches and a number of transdermal 17- ⁇ estradiol and norethindrone acetate patches. Each patch may be individually sealed in a protective pouch.
• a first 17- ⁇ estradiol patch may be applied for the required number ot days (although it is not essential to start with this phase), this patch is removed and one ot the 17- ⁇ estradiol and norethindrone acetate patches is applied tor the required number ot days. The second patch is then removed and another 17- ⁇ estradiol patch is applied, and so on.
• the treatment is normally continued without interruption.
• the individual patches are usually changed every three or tour days depending on the particular regimen, although the patches may be prepared tor application tor any combination ot days within the one to tour days limitation tor the regimen.
• Each new patch is applied to a different site.
• Preferred application sites are clean, dry and intact areas of skin, below the waistline on the trunk ot the body.
• Preferably the buttock, hip or abdomen area is chosen since these areas of skin wrinkle least during body movement.
• EXAMPLE 1 A three-day phase transdermal patch of 17- ⁇ estradiol ( 100 ⁇ g/day) is administered and alternated with a three-day phase transdermal patch of 17- ⁇ estradiol ( 100 ⁇ g/day) and norethindrone (.35 mg/day). These patches are applied alternately and without interruption.
• EXAMPLE 2 A three-day phase transdermal patch ot 17- ⁇ estradiol ( 100 ⁇ g/day) is administered and alternated with a three-day phase transdermal patch of 17- ⁇ estradiol ( 100 ⁇ g/day) and norethindrone acetate (0.35 mg/day). These patches are applied alternately and without interruption.
• a three-day phase transdermal patch of 17- ⁇ estradiol (50 ⁇ g/day) is administered and alternated with a three-day phase transdermal patch of 17- ⁇ estradiol (50 ⁇ g/day) and norethindrone acetate (0.15 mg/day). These patches are applied alternately and without interruption.
• EXAMPLE 4 A three-day phase transdermal patch of 17- ⁇ estradiol (25 ⁇ g/day) is administered and alternated with a three-day phase transdermal patch of 17- ⁇ estradiol (25 ⁇ g/day) and norethindrone acetate (0.50 mg/day). These patches are applied alternately and without interruption.
• EXAMPLE 5 An estrogen patch using an ethanolic gel type of drug reservoir incorporating about 4 mg. of 17- ⁇ estradiol is prepared having a surface area of about 18 cnr. In appearance it is round with the reservoir comprising about 10 cnr of the patch. This generally provides a transdermal delivery rate of about 10 ⁇ g/day for 17- ⁇ estradiol.
• An estrogen/progestin patch is prepared using an ethanolic gel type of drug reservoir with the amounts of hormones comprising 10 mg of 17- ⁇ estradiol and 30 mg of norethindrone acetate.
• the total contact area of such a patch is about 20 cm 2 .
• the patches have the appearance of eyeglasses with two joined reservoirs with each reservoir containing both drugs. These patches generally provide a transdermal delivery rate of 50 ⁇ g/day of 17- ⁇ estradiol and 250 ⁇ g/day of norethindrone acetate.
• the patches are packaged in cartons containing a number of transdermal 17- ⁇ estradiol patches and a number of transdermal 17- ⁇ estradiol and norethindrone acetate patches. Each patch is individually sealed in a protective pouch.
• a first 17- ⁇ estradiol patch is applied for the required three days (although it is not essential to start with this phase), this patch is removed and one of the 17- ⁇ estradiol and norethindrone acetate patches is applied for four days. The second patch is then removed and another 17- ⁇ estradiol patch is applied, and so on. The treatment is continued without interruption.
• Each new patch is applied to a different site.
• Preferred application sites are clean, dry and intact areas of skin, below the waistline on the trunk of the body.
• the buttock, hip or abdomen area is chosen since these areas of skin wrinkle least during body movement.
• transdermal delivery systems are perceived to exist primarily in the ability to bypass the liver on the "first pass" of the hormones through the body, by not delivering them orally.
• the advantage of avoiding the liver is that lower amounts of the drug can be given to a patient in order to achieve the same degree of efficacy in target tissues, thereby diminishing the untoward metabolic effects (e.g., changes in coagulation factors, glucose metabolism, lipids, etc.) that would be encountered via the oral route. It is also thought that avoidance of the stomach could prevent some of the nausea and gastrointestinal distress that is associated with estrogen therapy when taken orally.
• Estrogen replacement therapy is known to relieve hot flushes and this relief of flushes and night sweats improves sleep patterns and contributes to the patient's general feeling of well-being.
• Estrogen replacement protects against postmenopausal loss of calcium from the skeleton, especially from vertebral bodies, preventing crush fractures and loss of body height.
• Estrogen replacement has also been shown to improve the vascuiarity and health of the vaginal mucosa and urinary tract.

Applications Claiming Priority (3)

Publications (1)

Family

ID=25543344

Family Applications (1)

Country Status (8)

Families Citing this family (1)

Family Cites Families (2)

• 1993
  • 1993-12-24 CA CA002152780A patent/CA2152780A1/en not_active Abandoned
  • 1993-12-24 EP EP94904111A patent/EP0675720A1/de not_active Withdrawn
  • 1993-12-24 WO PCT/CA1993/000564 patent/WO1994014450A1/en not_active Application Discontinuation
  • 1993-12-27 SI SI9300687A patent/SI9300687A/sl unknown
  • 1993-12-27 ZA ZA939686A patent/ZA939686B/xx unknown
  • 1993-12-27 IL IL10818393A patent/IL108183A0/xx unknown
  • 1993-12-28 CN CN93121739A patent/CN1097987A/zh active Pending
• 1994
  • 1994-01-03 MX MXPA94000108A patent/MXPA94000108A/es unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events